Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 1.00 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urb-597 SCHEMBL93842 | 1.00 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14187855 | 0.99 | FAAH (0.98) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL17175654 | 0.96 | FAAH (0.93) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL4750537 | 0.92 | FAAH (0.86) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.92 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14188106 | 0.90 | FAAH (0.82) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL16118260 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14722820 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL17165898 | 0.89 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL18685448 | 0.89 | FAAH (0.80) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3762034-B1 | A FATTY ACID AMIDE HYDROLASE (FAAHI) INHIBITOR FOR USE IN INHIBITING THE CELLULAR ACCUMULATION OF A SPHINGOLIPID IN A SUBJECT THAT HAS LYSOSOMAL STORAGE DISEASE OR DISORDER | WYLDER NATION FOUND (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4583859-A2 | COMPOSITIONS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | The Regents of University of California (US) | 2025-07-16 | — | — | EP | claimed |
| CN-119326745-A | Application of URB597 in preparation of medicine for treating chronic traumatic encephalopathy | 天津医科大学总医院 | 2025-01-21 | — | — | CN | claimed |
| WO-2024225481-A1 | AGENT FOR IMPROVING THERAPEUTIC RESPONSIVENESS IN CANCER IMMUNOTHERAPY WITH PD-1 INHIBITOR OR PD-L1 INHIBITOR | 国立大学法人京都大学 | 2024-10-31 | — | — | WO | claimed |
| US-20240252486-A1 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | UNIV CALIFORNIA (US) | 2024-08-01 | — | — | US | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024055006-A2 | COMPOSITIONS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-14 | — | — | WO | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2022204140-A1 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| CN-114126617-A | Piezoelectric agonists for preventing or reversing abnormal amyloid deposition | 东芬兰大学 | 2022-03-01 | — | — | CN | disclosed |
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220041552-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-10 | — | — | US | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | FAAH 51/4885TRPA1 2709/4885EPHX2 528/4885 |
| US-20220041552-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPA1 | FAAH 318/4885TRPA1 3/4885EPHX2 748/4885 |
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | NLN, CASP3, BAX | FAAH 1839/4885TRPA1 3242/4885EPHX2 2521/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | FAAH 913/4885TRPA1 13/4885EPHX2 870/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | FAAH 69/4885TRPA1 4562/4885EPHX2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.